Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Cipargamin in Uncomplicated Malaria
NCT03334747Phase 2Completed
- Sponsor
- Novartis
- Start
- Nov 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of cipargamin in Plasmodium falciparum malaria, sponsored by Novartis. Started Nov 2017; status: completed.
02
Drugs
cipargamin
03
Conditions
Plasmodium falciparum malaria
Beyond the preview
Go deeper on NCT03334747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334747.